Novo bets against Crispr for amyloidosis
Novo moves into amyloidosis not long after Intellia made a splash here.
Why Glaxo should buy Biohaven
And four other potential targets that could make sense for the beleaguered group.
Combining forces in metabolic disorders
Altimmune’s early-stage obesity hit is impressive, but big pharma has more advanced rivals.
Glaxo needs long-acting HIV gamble to pay off
Dolutegravir’s patent expiry will pile on the pressure as Gilead and Merck get on the long-acting bandwagon.
Glaxo set to ask investors to keep the faith
The beleaguered big pharma is under huge pressure to change minds at Wednesday’s investor event.
The next wave of amyloid-targeting projects approaches
Acumen is the latest player to take aim at amyloid, but competition is fierce.
Why not bapineuzumab?
Like Aduhelm this long-discontinued amyloid beta MAb reduced brain beta amyloid; so have several other industry projects.
Medtronic bows to the inevitable
Paying $1.1bn for Heartware five years ago was not the company’s smartest move.
Toxicity concerns send Larimar down
The company hopes that its novel approach in Friedreich’s ataxia could still have legs, but other assets are further ahead.
